ArticleMetabolomics : Official journal of the Metabolomic Society2026
Lipidomic profile of meningiomas harboring different NF2 mutation status.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionMeningiomas are mainly benign brain tumors, but they can evolve to higher grades. The phenomena of these changes are not well-known. Therefore, more basic research is needed. This study attempted to assess the lipidome profile in meningiomas harboring different NF2 mutation statuses (wildtype and mutated). Solid-phase microextraction (SPME) probes were used to sample and extract the metabolites and reduce the invasiveness of lipidomic analysis.
objectivesThis study aimed to select the set of lipids distinguishing meningiomas with different genotypes using two chromatography methods (hydrophilic interaction chromatography (HILIC) and reversed-phase chromatography (RPLC) in two ionization modes.
methodsBrain tumors were obtained during neurosurgical procedures. Then, sampling using SPME fibers was performed directly after the lesion excision. After collecting the whole batch of samples, desorption using an isopropanol-methanol solution was performed. Subsequently, instrumental analysis was carried out using liquid chromatography coupled with high-resolution mass spectrometry. The remaining part of the lesion was stored as paraffin tissue blocks, and then genetic testing was performed to determine the presence of mutations in the NF2 gene.
resultsGenetic profiling of meningiomas revealed that most lesions had a mutation in the NF2 gene. A wide range of analytes was extracted from the studied tumors using SPME probes. A set of 34 lipids was selected as crucial metabolites in tumor differentiation. A combination of analytes detected in more than one analysis mode demonstrated higher sensitivity and specificity compared to the individual models and increased the differentiation of mutant and wildtype samples.
conclusionsSPME coupled liquid chromatography and mass spectrometry, can be successfully applied to the screening of lipids in meningiomas with different NF mutation statuses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.